Publikation
Treatment of advanced cutaneous T-cell lymphomas with non-pegylated liposomal doxorubicin--consensus of the lymphoma group of the Working Group Dermatologic Oncology
Wissenschaftlicher Artikel/Review - 02.01.2013
Assaf Chalid, Becker Jürgen C, Beyer Marc, Cozzio Antonio, Dippel Edgar, Klemke Claus-Detlev, Kurschat Peter, Weichenthal Michael, Stadler Rudolf
Bereiche
PubMed
DOI
Zitation
Art
Zeitschrift
Veröffentlichungsdatum
eISSN (Online)
Seiten
Kurzbeschreibung/Zielsetzung
BACKGROUND
Systemic treatment with pegylated liposomal doxorubicin is an established second-line treatment of advanced cutaneous T-cell lymphoma. Pegylated liposomal doxorubicin (PLD) is currently unavailable, therefore, clinical studies investigating the efficacy of non-pegylated liposomal formula (NPLD) have been analyzed.
METHODS
Since clinical trials comparing PLD and NPLD in CTCL do not exist, the clinical use of NPLD including safety and efficiency profile in other types of non-Hodgkin lymphoma were analyzed.
RESULTS
Clinical trials show a comparable efficacy of NPLD and PLD in non-Hodgkin lymphoma. The dosage of NPLD used in the treatment of systemic lymphoma within polychemotherapy regimens was 50 mg/m2 every three weeks. Overall response was 75-95%, including a complete remission rate of 65-80% and 2- and 3-year overall survival rates of 55-75%. These data indicate that the non-pegylated formula of doxorubicin has a similar antitumor effect as the pegylated one but shows reduced cardiotoxicity. The palmoplantar erythrodysesthesia frequently observed in PLD has not been observed with the use of the NPLD.
CONCLUSIONS
The clinical use of NPLD in the treatment of CTCL is reasonable. In analogy to the clinical trials of NPLD in non-Hodgkin lymphoma a dosage of 50 mg/m(2) every three weeks is recommended for the treatment of CTCL.